Everybody 12 /Case Studies 0 /Conferences 9 /FreeMind Elite 0 /FreeMind Elite 2024 0 /FreeMind Elite 2025 0 /Job posting 0 /NDFS 2025 Presentations 0 /NDFS 2026 Presentations 0 /News 2 /Opinions 0 /Opportunities 2 /Presentations 0 /Uncategorized 2 /Webinars 0

AgeingFit Event – 8th edition March 11th & 12th 2024 in Lille (France)

June 18, 2023/by Ayal Ronen

BioFIT – 12th edition takes place from 12th to 13th December in Marseille!

June 15, 2023/by Ayal Ronen

23RD ANNUAL BIOTECH IN EUROPE FORUM FOR GLOBAL PARTNERING & INVESTMENT 20TH-21ST SEPTEMBER 2023 | MÖVENPICK HOTEL | BASEL | SWITZERLAND

June 15, 2023/by Ayal Ronen

FreeMind Investments (FMI) update: Daewoong Pharmaceuticals, HanAll Biopharma, and FreeMind Investments co-invest in Vincere Biosciences’ mitochondrial small molecule program

June 12, 2023/by Ayal Ronen

BioFuture – October 4-6, 2023 NYC

May 31, 2023/by Ayal Ronen

RNA Leaders USA Congress – Boston, MA 6-7, 2023

May 17, 2023/by Ayal Ronen

Peer Reviewed Cancer Research Program (PRCRP)

April 13, 2023/by Ayal Ronen

19th Annual Anglonordic Life Science Conference – April 20, 2023 – London

April 2, 2023/by Ayal Ronen

FreeMind supports MedFIT 2023! October 10th, Strasbourg, France

March 30, 2023/by Ayal Ronen

BioTrinity – London

March 22, 2023/by Ayal Ronen
Get 10% off Sachs Associates' 9th Annual Immuno-Oncology Innovation Forum #Sachs_IOIF, June 2, at the Waldorf Astoria Chicago. The programme is designed to discuss key industry trends and milestones on the eve of the ASCO meeting. The event brings together leaders from cancer research institutes, patient advocacy groups, pharma and biotech, and Wall Street, to facilitate partnering, funding and investment. We anticipate around 250 delegates and 25+ company presentations by established and emerging companies with part of the audience participating virtually. We've secured a 10% discount on registration for members of our network. (Just say you're with FreeMind when you register.) There's also a limited number of complimentary passes for qualified institutional (buy/sell-side), private equity, and venture investors.

Sachs Associates’ 9th Immuno-Oncology Innovation Forum

March 21, 2023/by Ayal Ronen
ARPA-H announces its first funding opportunity

ARPA-H Announces 1st Funding Opportunities

March 19, 2023/by Ayal Ronen

Recent Posts

Followon XSubscribeto RSS Feed

Reach out to us with your non-dilutive funding requirements